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ABSTRACT 27 
 28 
The present EC surveillance regulations require discriminatory testing of all 29 
transmissible spongiform encephalopathy (TSE) positive small ruminant 30 
samples, in order to classify them as BSE or non-BSE. This requires a range 31 
of tests including, characterisation by bioassay in mouse models. Since 2005 32 
naturally-occurring BSE has been identified in two goats. It has also been 33 
demonstrated that more than one distinct TSE strain can co-infect a single 34 
animal in natural field situations.  35 
This study assesses the ability of the statutory methods as listed in the 36 
regulation to identify BSE in a blinded series of brain samples in which ovine 37 
BSE and distinct isolates of scrapie are mixed in varying ratios from 99% to 38 
1%.  Additionally, these current statutory tests were compared with that of a 39 
new in vitro discriminatory method which uses serial protein misfolding cyclic 40 
amplification (sPMCA).  41 
Western blotting consistently detected 50% BSE within a mixture, but at 42 
higher dilutions it had variable success. The ELISA method consistently 43 
detected BSE only when it was present as 99% of the mixture, with variable 44 
success at higher dilutions. Bioassay and sPMCA reported BSE in all samples 45 
where it was present, down to 1%. sPMCA could also consistently detect the 46 
presence of BSE in mixtures at 0.1%.   47 
While bioassay is the only validated method that allows comprehensive 48 
phenotypic characterisation of an unknown TSE isolate, sPMCA assay 49 
appears to offer a fast and cost-effective alternative for the screening of 50 
unknown isolates when the purpose of the investigation is solely to determine 51 
the presence or absence of BSE.  52 
 





The transmissible spongiform encephalopathies (TSE’s) are fatal 57 
neurodegenerative diseases of animals, of which scrapie in small ruminants is 58 
the archetype, and has been recognised as a disease in sheep and goats for 59 
almost 300 years although many aspects of the disease are still poorly 60 
understood. Despite the relative uniformity of the clinical signs, scrapie can be 61 
caused by ‘strains’ with differing biological and biochemical features [1,2]. 62 
Polymorphisms in the host PRNP gene, which encodes for the cellular protein 63 
PrPC, also influence scrapie susceptibility, strain selection and the ultimate 64 
disease phenotype displayed by the host [3,4].  Historically, the diversity of the 65 
scrapie agent has been demonstrated by the serial passaging of natural 66 
isolates to a panel of inbred mouse lines, but this does not provide a 67 
comprehensive and reliable picture of the diversity of the TSE agents in small 68 
ruminants. However, transgenic mice are proving to be susceptible to a wider 69 
range of TSEs, enabling more comprehensive characterisation of strains [2]. 70 
In 1998, the definition of ovine TSEs was extended by the discovery, in 71 
Norway, of an experimentally transmissible, neurological disease of sheep 72 
that was clearly distinguishable by all phenotypic parameters from the 73 
‘classical’ cases that had been reported so far. It was therefore considered to 74 
be an ‘atypical’ form of scrapie [4]. 75 
Despite similar diseases occurring in man (e.g. [5]) the animal TSEs were not 76 
regarded as zoonotic until the emergence in 1996 of variant Creutzfeldt-Jakob 77 
Disease (vCJD), linked to bovine spongiform encephalopathy (BSE) [6] which 78 
was first described in cattle in the 1980s [7]. 79 
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Experimental studies in food animal species showed the potential 80 
transmissibility of BSE to a range of alternative hosts [8] and it became clear 81 
that the small ruminant population had been potentially exposed to infection 82 
by dissemination through concentrate feed which may have contained 83 
contaminated meat and bone meal, implicated as the origin of the BSE 84 
epidemic in cattle [9].  85 
Experimental studies in sheep demonstrated that disease can result from oral 86 
challenge with cattle BSE [10] and, once established, it can transmit naturally 87 
[11]. In addition, the biological properties of the resulting ovine BSE in 88 
laboratory models indicate a potentially enhanced virulence for other species 89 
including man [12,13].  90 
Although ovine BSE has not yet been identified in the field, two naturally-91 
occurring cases of caprine BSE have been reported [14,15,16]. As a 92 
consequence of this potential risk of BSE in the small ruminant (SR) 93 
population, the current EC regulations (999/2001 as amended 36/2005) 94 
require the discriminatory testing of all TSE positive SR surveillance samples 95 
to enable the discrimination of BSE from classical scrapie in these samples. 96 
The phenotype of experimental ovine BSE [17] bears a clear resemblance to 97 
naturally-occurring scrapie, which is endemic in many sheep populations. 98 
However, there are some subtle differences in the biochemical signatures of 99 
these diseases. The disease-specific isoform (PrPSc), of the normal host 100 
protein (PrPC) is the target for all current TSE biochemical diagnostic tests. 101 
Depending on the TSE isolate, e.g. BSE or one of the various forms of 102 
scrapie, there are differences in the molecular location of protease K (pK) 103 
cleavage sites, and/or relative pK sensitivity.  These differences, as visualised 104 
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by comparing the relative binding of antibodies against various epitopes 105 
around these PK cleavage sites, form the basis of the discriminatory tests 106 
currently listed in the regulations, which use either immunohistochemistry 107 
(IHC) [18] Western blot (WB) [19,20] or ELISA [21] formats.  108 
In the absence of identified, naturally-occurring ovine BSE, the development 109 
and evaluation of the discriminatory tests which form the basis of the current 110 
EU statutory requirements was based on panels of samples comprising 111 
naturally-occurring classical scrapie, experimentally induced ovine BSE and 112 
bovine BSE all of which were demonstrated to be readily distinguishable by 113 
these tests [22].  114 
The only experimental study that has been undertaken [23], suggests that the 115 
picture with co-infection in sheep is complicated; the WB and IHC data from 116 
central nervous system (CNS) tissues resemble classical scrapie, while in the 117 
lymphoreticular system (LRS) they may resemble either classical scrapie or 118 
BSE. Subsequent bioassay using two transgenic models (tg110, a line which 119 
overexpresses bovine PrP on a null murine PrP background [24] and tg338, a 120 
line that overexpresses a VRQ allele of the ovine PrP on a null murine PrP 121 
background [25]) has shown that both BSE and scrapie can be identified by 122 
bioassay from the brains of these sheep despite only a classical scrapie signal 123 
being detectable on initial screening with WB and IHC [23]. These two 124 
transgenic mouse lines, used in combination, are widely accepted to be a 125 
robust approach to biological discrimination, because the ovinised line would 126 
preferentially propagate scrapie isolates, and the bovinised line would 127 
preferentially propagate BSE. They are endorsed by the EU Reference 128 
Laboratory Strain Typing Group in the guidance document for discriminatory 129 
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testing in the context of EU regulation 36/2005 (http://www.tse-lab-130 
net.eu/documents/tse-oie-rl-handbook.pdf).  131 
Although not a widely reported occurrence, there is evidence that animals can 132 
be naturally co-infected with atypical and classical scrapie [26] and 133 
experimentally with BSE and scrapie [23,27]. There are concerns that current 134 
in vitro tests would not be able to provide reliable discrimination in situations 135 
where a sheep or goat was co-infected with BSE and scrapie. This uncertainty 136 
applies to a lesser extent to bioassay models using wild-type mice [27,28] 137 
although transgenic models offer greater potential through differing strain 138 
susceptibility [29,30,31].   139 
Any in vitro mixing study cannot replicate a natural host co-infection situation, 140 
and results must not be extrapolated in that way. However, a preliminary 141 
estimate of how tests might perform can be sought through the testing of 142 
scrapie samples ‘spiked’ with BSE, and vice versa. Even this in vitro approach 143 
cannot cover all the potential variables relating to the scrapie isolates from 144 
donors, and issues such as the timing and route of infection (e.g. temporally 145 
separated, or not; same route, or not; compatibility of donor and recipient 146 
genotypes; age at challenge etc.) without becoming unworkably complicated, 147 
so the study reported here must be viewed in this context.  148 
Recently, a new in vitro method has been developed [32] that exploits the 149 
differential amplification of PrPSc from BSE and classical scrapie sources in 150 
different substrates using serial protein misfolding cyclic amplification 151 
(sPMCA), with retention of strain-specific biochemical characteristics. 152 
Although presently sPMCA is not a statutory test it was included 153 
retrospectively in this blinded assessment to enable a preliminary direct 154 
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comparison of this new discriminatory approach with the current statutory 155 
discriminatory methods, including the bioassay ‘gold standard’.  156 
 157 
MATERIALS AND METHODS 158 
Materials 159 
Experimentally generated ovine classical BSE [17] and four different naturally 160 
occurring scrapie isolates which had been characterised pathologically, 161 
biochemically and biologically, were sourced (see Table 1 for details) and 162 
prepared as a 10% (w/v) homogenate in 0.85% sterile saline [33,34].  For 163 
each scrapie source selected, the ovine BSE was mixed with it at 1%, 10%, 164 
25%, 50%, 75%, 90% and 99% based on volume. These mixtures, together 165 
with the neat ovine BSE and scrapie samples were subdivided into aliquots, 166 
blinded and stored frozen as test panels comprising 33 samples (Panel 1).  167 
Estimations of the PrPres (the proteinase K (PK) resistant moiety of PrPSc 168 
which is usually detected by biochemical tests such as Western blot and 169 
ELISA) present in each ‘neat’ sample were obtained so that estimates of the 170 
relative proportions of PrPres contributed by the two components of the mixture 171 
could be calculated retrospectively, but this did not affect the choice of 172 
material, since known biological phenotype criteria (i.e. distinct bioassay 173 
characteristics) were considered more relevant for this study.  174 
The sample panels were provided ‘blinded’ to teams in the APHA (for 175 
discriminatory Western blotting) and CEA laboratories (for discriminatory 176 
ELISA), and both laboratories were asked to provide an initial interpretation of 177 
‘BSE-like’ or ‘not BSE-like’ before samples were de-coded; samples were also 178 
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provided to ADAS/University of Nottingham for sPMCA analysis, and were 179 
similarly interpreted before decoding.  180 
All the neat sources used to prepare the panel were selected for bioassay in 181 
transgenic mice, together with the mixture with the highest undetectable 182 
percentage of BSE and the mixture containing 1% BSE from each 183 
scrapie/BSE combination. For animal bioassays, a bovinised (tg110) and an 184 
ovinised (tg338) mouse line were used.  A total of 24 assays were performed. 185 
 186 
 187 
Discriminatory Western blot 188 
The samples were subjected to discriminatory Western immunoblotting using 189 
the APHA BioRad-Hybrid Western blot method as described in detail in the 190 
EU discriminatory testing handbook (http://www.tse-lab-net.eu/documents/tse-191 
oie-rl-handbook.pdf). TSE strains can be characterised as ‘classical’ or 192 
‘atypical’ based on the profile of the protein bands detected by different 193 
antibodies following Western immunoblotting. Within this study, the PrP forms  194 
in the sample panel tested originated from either classical scrapie , classical 195 
ovine BSE or atypical scrapie. 196 
Classical forms of TSE typically present with a 3 band profile consisting of a 197 
diglycosylated (top), monoglycosylated (middle) and diglycosylated (bottom)  198 
pattern and a high molecular mass migration of the unglycosylated  PrP band 199 
with the core antibody (SHA31) and a similar or stronger intensity of overall 200 
signal with the N-terminal antibody (P4) is observed for classical scrapie. A 201 
low molecular mass migration of the unglycosylated  PrP band with the core 202 
antibody (SHA31) and a much reduced, or lack of, intensity of overall signal 203 
with the N-terminal antibody (P4) is observed for classical ovine BSE. Atypical 204 
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scrapie typically presents with a four band profile where all bands give a 205 
distinctive downward shift with the lowest band at 15kD or lower.  206 
 207 
The resulting band profile for each sample was visually assessed and 208 
categorised based on the above criteria. (Figure 1) The initial WB results were 209 
reported as BSE, scrapie or a mixture in which the BSE and each of the 210 
scrapie sources were provisionally classified 211 
 212 
Discriminatory ELISA 213 
The samples were tested in duplicate, using the discriminatory ELISA method 214 
that has been described in detail elsewhere [21]. This method treats each 215 
sample with one of two different PK digestion protocols (mild and stringent), 216 
and expresses the subsequent differences in antibody binding as a ratio. This 217 
ratio is further normalised against the BSE control sample in each assay run. 218 
Three internal controls were included: one classical scrapie sample (highly PK 219 
resistant, normalised ratio inferior to 0.3), an unusual scrapie sample 220 
previously reported [21] to give an ‘intermediate’ result (PK resistant, 221 
normalised ratio comprised between 0.3 and 0.7) and an experimental BSE 222 
sample (PK sensitive, normalised ratio comprised between 0.7 and 1.3).  223 
According to these values, the blinded samples were categorised as ‘scrapie’, 224 
‘intermediate scrapie’ or ‘BSE’.  Samples with a normalised ratio above 1.3 225 
were classified as ‘atypical scrapie’.  226 
 227 
PrPres estimation 228 
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Aliquots of the un-mixed 10% brain homogenates (in normal saline) of ovine 229 
BSE and scrapie were pelleted out by high-speed centrifugation and re-230 
homogenised in Bio-Rad TeEsE ELISA kit proprietary buffer to give 20% w/v 231 
as specified in the kit instructions. A dilution series of each isolate was 232 
prepared, and samples were analysed in accordance with the manufacturer’s 233 
instructions. The end point dilution assays were used to generate PrPres 234 
protein estimations for each homogenate (Table 1), and these were 235 
normalised for the ovine BSE sample.  236 
 237 
Animal bioassays 238 
All intracerebral inoculations were carried out under general anaesthesia, and 239 
in accordance with the United Kingdom (UK) Animal (Scientific Procedures) 240 
Act 1986, under Licence from the UK Government Home Office (Project 241 
licence number 70/7159). Such licences are only granted following approval 242 
by the internal APHA ethical review process as mandated by the Home Office. 243 
Each inoculum (10% w/v brain homogenate in normal saline) was used to 244 
challenge 10 tg110 and 10 tg338 mice intracerebrally (20µl per mouse).  The 245 
mice were allowed to develop TSE disease and were euthanized when they 246 
reached terminal disease stage, or due to other welfare reasons. At post 247 
mortem each brain was sectioned parasagitally; 2/3 was fixed and 248 
subsequently processed for histology and immunohistochemistry whilst the 249 
remaining 1/3 was kept frozen.   250 
All samples were examined for the presence of TSE specific vacuolation in 251 
H&E slides and for PrPSc detection using immunohistochemistry with the 252 
polyclonal antibody Rb486 according to standard methodology as previously 253 
described [34].  254 
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 255 
Discriminatory sPMCA 256 
 257 
Following completion of this ring trial and bioassay, a potentially discriminatory 258 
sPMCA method became available. This method, which is described in detail 259 
elsewhere [32], uses five sPMCA rounds with AHQ/AHQ and VRQ/VRQ 260 
sheep brain homogenates as the substrates being used in alternate rounds, 261 
followed by PK digestion and visualisation in WB using the monoclonal 262 
antibody (mAb) SHa31. This method selects for the amplification of BSE, but 263 
not scrapie.  264 
Amplified products that are detected in WB are then additionally probed 265 
separately by both P4 and SHa31 antibodies in order to confirm BSE status.   266 
A panel of original aliquots from this comparative study was supplied, blinded, 267 
for testing (Panel 1), then, following initial results Panel 2, generated from the 268 
original sources, and extending the dilution range of the ovine BSE to 269 




Estimated PrPres concentration in the brains of the sources that contributed to 274 
the mixtures 275 
 276 
The PrPres concentration in the brains of the sources that contributed to the 277 
mixtures is shown in Table 1. There was less than 1 log difference between 278 
the concentration of PrPres in the ovine BSE source and each of the scrapie 279 
sources. Assuming that PrPres is a reliable indicator for infectivity, the ratios of 280 
BSE relative to scrapie in the series of mixtures used in this study is accurate 281 
within 0.27-0.63 logs depending on the classical scrapie source.  With the 282 
exception of the VRQ/VRQ classical scrapie source, the PrPres concentration 283 
in the BSE source was lower compared to the other scrapie sources.  284 
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Therefore, with the exception mentioned above, in the mixtures of scrapie 285 
sources with BSE the concentration of PrPres attributed to scrapie was higher 286 
than that indicated by the percentage ratio of the scrapie source in the 287 
mixture.   288 
 289 
Discriminatory Western blot  290 
The WB results for each sample were recorded using the following criteria; 291 
high or low molecular migration with the core antibody (SHa31); strong, 292 
medium, weak or negative with the N-terminal antibody (P4) and a description 293 
of either classic 3 band or atypical profile for each antibody. Using the 294 
combination of results, each sample was assigned a concluding result of BSE, 295 
scrapie, atypical scrapie or a description of combined TSE types. 296 
Representative descriptions for 14 blinded samples are presented in Table 2, 297 
with corresponding Western blots shown in Fig 1. 298 
 299 
Western blotting could consistently detect BSE present within a mixture with 300 
scrapie when it was present as 50% of the mixture (Table 3). 301 
 302 
Discriminatory ELISA 303 
The ELISA method could consistently detect BSE when mixed with scrapie 304 
when it was present as 99% of the mixture (Table 3). However the results vary 305 
depending on the scrapie strains. BSE was detected when it was present as 306 
75% of the mixture (for classical scrapie VRQ/VRQ and ARQ/ARQ), 90% 307 
(classical scrapie 1-4-7 ARQ/ARQ) or 99% (atypical scrapie). When the data 308 
are unblinded, and the ELISA results grouped by scrapie type (Figure 2) it can 309 
be seen that this apparent inability to detect BSE is partly due to the 310 
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restrictions of having a numerical result and cut-offs. There is no qualitative 311 
data to aid interpretation of ‘intermediate’ cases.  312 
 313 
A summary of the ability of the biochemical tests to discriminate BSE in the 314 
presence of scrapie, at a ratio of 1% to 99% (Panel 1) when the samples are 315 
blinded, is presented in Table 3. Different isolates resulted in different 316 
discriminatory thresholds, which were different between the tests. For 317 
example, BSE could be detected at very low levels against a background of 318 
atypical scrapie in the WB, but the BSE signal was masked by small amounts 319 




Mixtures of BSE with VRQ/VRQ or ARQ/ARQ classical scrapie 324 
Both tests, WB and ELISA, failed to identify the presence of BSE in the 325 
dilution series when its ratio in the mixture with VRQ/VRQ classical scrapie 326 
dropped below 50% (Table 3). Therefore the inoculum just below the cut-off 327 
point (25% BSE ratio relative to scrapie) and the inoculum with the lowest 328 
BSE ratio relative to scrapie (1% BSE) were subjected to bioassays. WB and 329 
ELISA also failed to identify the presence of BSE when the ratio of BSE to 330 
ARQ/ARQ classical scrapie was below 25% (Table 3). Therefore the inocula 331 
with 10% and 1% BSE concentration relative to scrapie were subjected to 332 
bioassays.   333 
In tg338 mice the scrapie agents isolated from both classical scrapie sources 334 
were indistinguishable, with very short incubation periods - 69.5 and 75.5 335 
mean dpi for VRQ/VRQ and ARQ/ARQ scrapie isolates respectively (Figures 336 
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3A and 4A), similar lesion profiles (Figures 3B and 4B) and similar brain 337 
distribution of PrPSc types as assessed by IHC (data not shown).   338 
All tg338 mice that were challenged with BSE succumbed to TSE 624 dpi or 339 
later (Figure 3A).  In contrast, inoculation of tg338 mice with BSE mixed with 340 
either the VRQ/VRQ or the ARQ/ARQ classical scrapie sources produced 341 
incubation periods less than 90 dpi that were compatible with those produced 342 
by the respective scrapie sources alone (Figures 3A and 4A).  These data 343 
indicate that the component isolated in the mice from the BSE mixtures with 344 
VRQ/VRQ or ARQ/ARQ classical scrapie only had classical scrapie 345 
properties.  The vacuolation lesion profiles alone were not conclusive because 346 
the VRQ/VRQ and the ARQ/ARQ classical scrapie, and BSE profiles were not 347 
dissimilar enough to allow unequivocal interpretation, although the mixtures 348 
did align more closely with the classical scrapie profiles produced by the 349 
100% scrapie sources (Figures 3B and 4B).   350 
All tg110 mice challenged with the VRQ/VRQ source were TSE negative or, in 351 
the case of the ARQ/ARQ source, showed low attack rates with the first 352 
positive animal identified 581 dpi (Figures 3A and 4A).  In contrast, mixtures of 353 
BSE with either VRQ/VRQ or ARQ/ARQ classical scrapie produced clinical 354 
stage TSE with incubation periods of 236-326 dpi (Figures 3A and 4A).  These 355 
incubation periods are comparable with those generated by the original BSE 356 
source (221-267 dpi) albeit slightly longer, probably as a result of the slightly 357 
reduced titre of BSE in the mixtures.  These data suggest that in this mouse 358 
line only the BSE component was isolated from the mixtures.  The lesion 359 
profiles from the tg110 mice (Figures 3C and 4C) further support the 360 
conclusion that the isolated agent had only BSE properties although it was not 361 
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possible to construct lesion profiles from either scrapie source due to the lack 362 
of sufficient clinically positive mice diagnosed with TSE.  363 
 364 
1-4-7 ARQ/ARQ classical scrapie and ovine BSE 365 
 366 
Both tests failed to identify the presence of BSE in the dilution series when its 367 
concentration in the mixture dropped below 50% (Table 3). Therefore the 368 
inoculum just below the cut off point (25% BSE ratio relative to scrapie) and 369 
the inoculum with 1% BSE ratio relative to scrapie were subjected to 370 
bioassay.   371 
Figure 4A shows that tg338 mice challenged with either of these mixtures 372 
succumbed to disease with incubation periods that were compatible with the 373 
incubation periods produced by the scrapie source alone, indicating that the 374 
agent isolated from the 25% and 1% BSE mixtures was the scrapie 375 
component. The lesion profiles are not conclusive because the ARQ/ARQ 376 
scrapie and BSE profiles are indistinguishable (Figure 5B).   377 
The incubation periods of tg110 mice challenged with the 1-4-7 classical 378 
scrapie isolate were relatively shorter than the incubation periods caused by 379 
BSE in this mouse line (Figure 5A). The incubation periods produced by the 380 
25% and 1% BSE mixture in this mouse line were aligned with the incubation 381 
periods produced by the 1-4-7 ARQ/ARQ classical scrapie source (Figure 5A).  382 
Lesion profiles concur with this interpretation as the lesion profiles produced 383 
by the mixtures align with the lesion profile of the 1-4-7 classical scrapie whilst 384 
BSE produces a distinct separate profile (Figure 5C).  385 
  386 
Tg110 mice challenged with either the scrapie or the BSE source succumbed 387 
to disease with relatively short incubation periods, therefore the mice 388 
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inoculated with the mixtures were further compared to those challenged with 389 
the original sources using immunohistochemistry (IHC) (Figure 6).   390 
Tg110 mice challenged with the 1-4-7 classical scrapie source showed a 391 
pattern characterised by intraneuronal and fine punctate PrPSc deposits in the 392 
neuropil; when aggregates were present they were distinct, well demarcated 393 
and ovoid (Figure 6A).  BSE challenged tg110 mice also showed 394 
intraneuronal PrPSc but the neuropil was populated with diffuse granular 395 
deposits, coalescing aggregates and plaque-like formations (Figure 6B). In 396 
addition to the IHC attributes associated with the 1-4-7 classical scrapie 397 
pattern, tg110 mice challenged with either mixture additionally showed 398 
features that were associated with the BSE-induced pattern (Figures 5C and 399 
5B). This BSE associated pattern also appeared to be more extensive in the 400 
mice that were challenged with the 25% BSE mixture compared with the mice 401 
that received the 1% BSE mixture.   402 
Although the incubation periods and the lesion profiles, particularly those 403 
generated by mice that were inoculated with 25% BSE mixture, suggest that 404 
the BSE agent did not propagate selectively in the tg110 mice, it was still 405 
possible to identify the BSE component reliably in the Tg110 mice using IHC.     406 
 407 
Atypical scrapie and ovine BSE 408 
 409 
Both WB and ELISA failed to identify the presence of BSE in the dilution 410 
series when its concentration in the mixture dropped below 10% (Table 3). 411 
Therefore the inoculum with 1% BSE concentration relative to scrapie was 412 
subjected to bioassays.  413 
The incubation period data in tg338 indicate that the agent isolated from these 414 
mixtures was compatible with the agent isolated from the atypical scrapie 415 
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source; in tg110 mice the incubation period data indicate that agent isolated 416 
from the mixtures was compatible with the agent isolated from the BSE source 417 
(Figure 7A). The lesion profiles from tg338 (Figure 7B) and tg110 mice (Figure 418 
7C) provide further support to the incubation period data although it was not 419 
possible to construct lesion profiles from the scrapie source in tg110 as all of 420 
the mice challenged with this source were TSE negative.  421 
 422 
Discriminatory sPMCA  423 
 424 
The original panel of 33 samples (Panel 1) were all correctly reported as ‘BSE 425 
present’, with the correct exception of the un-mixed scrapie samples (Table 426 
3). The analysis of Panel 2 gave identical results for the 1% to 99% mixtures.  427 
sPMCA also correctly reported the presence of BSE in all samples in which 428 
BSE was diluted to 0.1%. BSE was also successfully detected in one sample 429 
where it was diluted to 0.01% with atypical scrapie (Figure 8).  430 
 431 
Discussion  432 
 433 
Co-infection studies in animals using mixtures of known infectious titre remain 434 
the hypothetical ideal for this type of study, but for several reasons such 435 
studies are not necessarily as appropriate as they might appear on initial 436 
consideration. The observed titre of a TSE isolate is not an absolute measure 437 
of the infectivity of that isolate, but is also affected by the susceptibility of the 438 
host, which may differ for different isolates. For example, some scrapie strains 439 
that readily infect sheep and transgenic mouse models do not cause disease 440 
in conventional inbred mouse lines [2,33]. Therefore it is unwise to assume 441 
that two isolates with similar observed levels of infectivity in any one model 442 
will necessarily have the same infectivity potential in other species, or indeed 443 
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in animals of different genotypes. Equally, PrPres concentration cannot be 444 
considered to be a consistent proxy for the level of infectivity in an isolate [37]. 445 
The interaction of strains either in vitro or within a single host is also very 446 
poorly understood. If strain properties are conferred by tertiary molecular 447 
structure, then mixing isolates together might affect the ability of a strain to 448 
infect a host either in an inhibitory or potentiating way. This may also affect 449 
tests applied to a sample with both isolates represented. However, the data 450 
from this study demonstrate that this is not the case, at least with the BSE and 451 
scrapie combinations used; all tests and models, except the sPMCA, could 452 
correctly classify both of the strains contributing to each of the mixtures, 453 
including the successful isolation, in mice, of all the component isolates of 454 
each mixture, with retention of the biological phenotypes of the unmixed 455 
controls.  456 
The bioassay data, particularly from the bovinised mice, also suggest that if 457 
sheep are exposed to both BSE and scrapie, the two agents will most likely 458 
propagate as independent entities according the dynamics of titre, time of 459 
exposure to each agent and ovine PrP genotype. Therefore exposure to both 460 
agents is unlikely to result in a novel agent with previously undetected 461 
biochemical or biological properties, although this possibility should always be 462 
considered when a new or unusual isolate is identified. Under these 463 
circumstances exposure to both agents would give rise to a mixture in which 464 
BSE can be detected with the current biochemical and biological tests 465 
provided that the titre of scrapie is not overwhelming. The data also show that 466 
the choice of diagnostic test, and which scrapie strain is present, both dictate 467 
the level of scrapie that “overwhelms” the detection of BSE. For BSE mixed 468 
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with atypical scrapie the presence of 10% scrapie masked BSE detection by 469 
ELISA whereas, at the other extreme, BSE mixed with atypical scrapie and 470 
detected by WB required the presence of above 90% scrapie to mask BSE.  471 
Additional unknowns, if trying to use an in vivo challenge model to recreate 472 
possible co-infection, are the age of the animal at challenge, the order in 473 
which the challenges occur, and possibly the length of time between the 474 
challenges [38,39,40]. 475 
The main purpose of this study was to attempt the identification of the BSE 476 
component of the mixture by using the approved discriminatory tests (EU 477 
regulation 36/2005), followed by discriminatory bioassay in tg338 mice to 478 
selectively propagate the scrapie strains, and tg110 mice to selectively 479 
propagate the BSE agent, in mixtures in which the identifiable biochemical 480 
signature of BSE has been lost or obscured. We conclude that the 481 
biochemical rapid tests can discriminate BSE in the presence of scrapie to 482 
varying degrees depending on the scrapie source, but this variation does not 483 
appear to be attributable to the amount of PrPres. The WB was more reliable 484 
than ELISA in discriminating BSE in the presence of scrapie, regardless of the 485 
scrapie isolate.  486 
The bioassay was capable of resolving cases of co-infection even where BSE 487 
represented just 1% of the total TSE infectivity. In order to achieve this, 488 
bioassay systems should include a bovinised mouse line that favours 489 
propagation of BSE over scrapie, and an ovinised line with complementary 490 
properties, i.e. a line that preferentially facilitates the propagation of scrapie 491 
prions over the BSE agent. In addition to the ability to identify BSE in mixed 492 
infections, bioassay continues to be the only validated method available that 493 
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enables the comprehensive phenotypic characterisation of an unknown 494 
isolate. 495 
It is probably not possible to source ‘ideal’ mouse lines with the above 496 
properties particularly as classical scrapie consists of various strains with 497 
widely variable properties. However, the selected mouse lines (tg338 and 498 
tg110) are as close as possible to that ideal situation and could be used in 499 
combination to resolve co-infection cases in a surveillance context if they 500 
arise. In addition, IHC may be useful to resolve a small proportion of 501 
bioassays in which the relative mouse line susceptibility is not, by itself, 502 
conclusive. 503 
Within this study, the new discriminatory sPMCA approach was the only in 504 
vitro method which consistently detected BSE when it was present in these 505 
mixtures, even at very low concentration (down to 0.1%). This sensitivity could 506 
potentially be exploited to screen pooled ovine TSE brain samples for the 507 
presence of BSE, greatly increasing the throughput, and decreasing the costs 508 
of such screening programmes in the future.  When the purpose of an 509 
investigation is solely to determine the presence or absence of BSE (as 510 
opposed to characterising whatever is in the isolate), this assay would appear 511 
to offer the potential for a fast and cost-effective alternative to bioassay, and 512 
will be proposed to the EURL Strain Typing Expert Group as a useful addition 513 
to the panel of tests currently used for the screening of unknown isolates.  514 
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Table 1. Estimation of PrPres concentration in the brains of the sources that 
contributed to the mixtures 
TSE source PrPres (μg/ml) Normalised for BSE Log10 
BSE1 2.2 1 0.00 
VRQ/VRQ classical scrapie2 1.0 0.45 -0.34 
ARQ/ARQ classical scrapie3 12.0 5.45 0.74 
1-4-7 ARQ/ARQ classical scrapie4 9.3 4.23 0.63 
Atypical scrapie (AHQ/ARQ)5 4.1 1.86 0.27 
1 Experimental ovine BSE produced and characterised at APHA  
2 Classical scrapie case supplied by Dr Olivier Andreoletti and characterised in tg338 
mice (PG 127 Classical scrapie [41]) 
3 Classical scrapie field case characterised at APHA (Scrapie 67 [35]) 
4 Classical scrapie field case characterised at APHA (Scrapie 19 [35]) The designation 1-
4-7 indicates a lesion profile in RIII mouse bioassay with peaks in areas 1,4 and 7, the 
same as seen with BSE isolates.  
5 Atypical scrapie field case (UK active surveillance) characterised and titrated (106.92 
LD50/gr) at APHA (unpublished data)   
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1 ++ Atypical NA  + Atypical Atypical scrapie 100% atypical scrapie 
2 +++ Classicalb  High  +++ Classical Classical scrapie 100% ARQ 147 scrapie 
3 +++ Classical Low  + NAc BSE 100% ovBSE 
4 +++ Classical High  +++ Classical Classical scrapie 100% VRQ scrapie 
5 +++ Classical High  +++ Classical Classical scrapie 100% ARQ scrapie 
         
6 +++ Classical Low  - NA BSE 99% ovBSE, 1% atypical scrapie  
7 +++ Classical Low  +++ Classical Scrapie with BSE 50%  ovBSE, 50% ARQ147 scrapie 
8 ++ Classical Low  ++ Atypical BSE with atypical  10% ovBSE, 90% atypical scrapie 
9 +++ Classical High  +++ Classical Scrapie 10%ovBSE, 90% VRQ scrapie 
10 +++ Classical Low  + Classical BSE with low dilution of 
scrapie or CH1641 
99% ovBSE, 1%ARQ147 scrapie 
11 +++ Classical Low  + Classical BSE with low dilution of 
scrapie or CH1641 
75%ovBSE, 25% atypical scrapie 
12 +++ Classical High  +++ Classical Scrapie 25%ovBSE,75%VRQ scrapie 
13 +++ Classical Low  ++ Classical BSE with scrapie 90% ovBSE, 10% ARQ scrapie 
14 ++ Atypical NA  ++ Atypical Atypical 1% ovBSE, 99% atypical scrapie 
a. Molecular mass of the unglycosylated band of a classical 3-band pattern 
b. Three band pattern associated with classical scrapie and BSE.  
c. Sample too weak to determine the banding pattern 
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Table 3  Ability of biochemical tests to identify BSE when mixed with 
different scrapie sources  (Panel 1) 
Scrapie source 
Ovine BSE source (%) in 
the mixture BSE detection 
  WB ELISA sPMCA
   
 100 (C) + + + 
     
Classical (VRQ/VRQ) 99 + + + 
 90 + + + 
 75 + + + 
 50 + - + 
 25* - - + 
 10 - ± + 
 1* - - + 
 0* - - - 
     
Classical (ARQ/ARQ) 99 + + + 
 90 + + + 
 75 + + + 
 50 + - + 
 25 + - + 
 10* - - + 
 1* - - + 
 0* - - - 
     
Classical (1-4-7 ARQ/ARQ) 99 + + + 
 90 + + + 
 75 + - + 
 50 + - + 
 25* - - + 
 10 - - + 
 1* - - + 
 0* - - - 
     
Atypical (AHQ/ARQ) 99 + + + 
 90 + - + 
 75 + - + 
 50 + - + 
 25 + - + 
 10 + - + 
 1* - - + 
 0* - - - 
(C) indicates the BSE source (100% BSE) that was used to create the pools..  The 
percentage in the other cells in the same column indicates the percentage of BSE in the 
mixture. The difference reflects the percentage of scrapie material in the mixture.  
Dotted lines indicate the limit below which both WB and ELISA failed to identify the BSE 
component in the mixture.   
+ BSE detected; - BSE not detected; + inconclusive result 
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Figures 720 
 721 
FIG 1. Representative Western Blot for blinded samples, using mAbs SHa31 722 
(upper panel) and P4 (lower panel). This is an original diagnostic blot, 723 
selected to illustrate the nature of the blots on which the initial blind 724 
interpretation was made. The samples represented in lane 1-14 contained 725 
either 100% of a pure form of each TSE strain used in the study (lanes 1-5) or 726 
varying mixtures of the TSE strains (lanes 6-14). Mixed samples exhibit 727 
multiple band patterns dependent on the actual TSE strains contained in each 728 
mix. Interpretation of each sample was based on the observation of the main 729 
characteristics described in the WB method section. Detailed description of 730 
the samples, and their interpretation, in lanes 1-14 can be found in Table 2.. 731 
B=classical bovine BSE control, O=classical ovine scrapie control, 732 
M=molecular mass marker.  733 
 734 
FIG 2  Discriminatory ELISA. The mixed samples were tested in duplicates in 735 
blinded conditions. Ovine BSE was mixed with A) atypical scrapie B) classical 736 
scrapie (VRQ/VRQ) C) classical scrapie (1-4-7 ARQ/ARQ) or  D) classical 737 
scrapie (ARQ/ARQ). The normalised ratio for classical scrapie samples, which 738 
are highly PK resistant, is less than 0.3, intermediate scrapie samples present 739 
a normalised ratio comprised between 0.3 and 0.7 and experimental ovine 740 
BSE samples have a normalised ratio between 0.7 and 1.3. Atypical scrapie 741 
samples have ratio greater than 1.3. According to these values, the blinded 742 
samples were categorised as "scrapie" (grey), "intermediate scrapie" 743 
(hatched), "BSE" (black) or "atypical scrapie" (white). 744 
 745 
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FIG 3  Bioassay data in tg338 and tg110 mice of 25% and 1% BSE mixtures 746 
with VRQ/VRQ classical scrapie. The original BSE and VRQ/VRQ classical 747 
scrapie sources that were used to produce the mixtures were also 748 
bioassayed.  (A) Incubation periods; (B) lesion profiles in tg338 mice; (C) 749 
lesion profiles in tg110 mice.   At least 5 clinically and histopathologically 750 
positive mice contributed to each lesion profile (solid lines) unless indicated 751 
(dashed line).   752 
 753 
FIG 4  Bioassay data in tg338 and tg110 mice of 10% and 1% BSE mixtures 754 
with ARQ/ARQ classical scrapie. The original BSE and ARQ/ARQ classical 755 
scrapie sources that were used to produce the mixtures were also 756 
bioassayed.  (A) Incubation periods; (B) lesion profiles in tg338 mice; (C) 757 
lesion profiles in tg110 mice.   At least 5 clinically and histopathologically 758 
positive mice contributed to each lesion profile (solid lines) unless indicated 759 
(dashed line).   760 
 761 
FIG 5  Bioassay data in tg338 and tg110 mice of 25% and 1% BSE mixtures 762 
with 1-4-7 ARQ/ARQ classical scrapie. The original BSE and 1-4-7 ARQ/ARQ 763 
classical scrapie sources that were used to produce the mixtures were also 764 
bioassayed.  (A) Incubation periods; (B) lesion profiles in tg338 mice; (C) 765 
lesion profiles in tg110 mice.   At least 5 clinically and histopathologically 766 
positive mice contributed to each lesion profile (solid lines) unless indicated 767 
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FIG 6  Immunohistochemistry of tg110 mice challenged with (A) 1-4-7 771 
ARQ/ARQ classical scrapie, (B) ovine BSE, C) mixture with relative BSE: 772 
scrapie ratio 1:3 (25% BSE) and (D) mixture with relative BSE:scrapie ratio 773 
1:99 (1% BSE).  All photos show rostral medulla at the same magnification.   774 
Black rectangles in A, B and D indicate areas that have been further 775 
magnified and presented as insets in the corresponding images.  The mice 776 
inoculated with the BSE:scrapie mixtures show BSE associated coalescing 777 
PrPSc patterns even at the lowest ratio of BSE:scrapie (D).   Red arrowheads 778 
show examples of neurons with intraneuronal PrPSc deposits; blue 779 
arrowheads point to patterns of coalescing PrPSc deposits; black arrowheads 780 
illustrate examples of neurons devoid of intraneuronal PrPSc deposits.   781 
 782 
FIG 7  Bioassay data in tg338 and tg110 mice of a 1% BSE mixture with 783 
atypical scrapie. The original BSE and atypical scrapie sources that were 784 
used to produce the mixtures were also bioassayed.  (A) Incubation periods; 785 
(B) lesion profiles in tg338 mice; (C) lesion profiles in tg110 mice.   At least 5 786 
clinically and histopathologically positive mice contributed to each lesion 787 
profile.   788 
 789 
FIG 8 Western blot of PK digested sPMCA products. Samples of BSE brain 790 
homogenate were diluted into 4 isolates of ovine scrapie positive brain homogenate 791 
of VRQ, ARQ, Atypical and 1-4-7 ARQ types, as indicated, at 1/10, 1/100, 1/1000 or 792 
1/10000 dilutions (labelled as 1-4 respectively). Samples were amplified in duplicate 793 
including an equal number of scrapie only samples. Positive sPMCA samples were 794 
then further analysed: single sPMCA sample replicates were re-digested with PK and 795 
immunoblotted using the antibodies SHa31 and P4 (as shown). Blotting controls 796 
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were positive sheep scrapie (+S) or BSE (+B) brain homogenates and an ovine BSE 797 
sPMCA positive sample (+BP). Molecular mass markers (M) at 20 and 30kDa are 798 
shown. Blots were probed with either SHa31 or P4 monoclonal antibodies. Samples 799 
were scored positive for BSE (as indicated) if over a signal threshold on the WB and 800 
using a SHa31/P4 WB ratio as previously described [32]. 801 
 802 








